Rarity Bioscience Sees Way Forward For superRCA Liquid Biopsy Platform, Despite Challenges

 
• By Barnaby Pickering
  
Rarity’s reimbursement challenges and strong investor pedigree underscore the peril and promise of the post-LDT rule world. (Shutterstock)

More from Diagnostics

More from Device Area